Stock 603707 NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Equities

603707

CNE100002WP3

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
13.7 CNY +5.14% Intraday chart for Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. +7.20% -8.67%
May. 01 NKFPharma Gets Nod to Register New Cancer Treatment MT
Apr. 27 Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of heparin-related products. The Company's main products include standard heparin raw materials, low molecular weight heparin raw materials and their preparations, such as heparin sodium raw materials, heparin sodium, enoxaparin sodium injection, dalteparin sodium injection and Naqu Heparin Calcium Injection. The Company mainly exports its products to the United States and European countries.

Number of employees: 1,451

Sales per Business

CNY in Million2022Weight2023Weight Delta
Preparation
70.5 %
2,458 66.2 % 2,772 70.5 % +12.75%
Standard Heparin API
25.4 %
1,110 29.9 % 997 25.4 % -10.12%
Contract Development and Manufacturing Organization and Other Products
3.9 %
140 3.8 % 154 3.9 % +9.58%
Other Business
0.2 %
5 0.1 % 9 0.2 % +87.76%

Sales per region

CNY in Million2022Weight2023Weight Delta
Foreign
73.3 %
2,548 68.7 % 2,875 73.3 % +12.82%
China
26.7 %
1,160 31.3 % 1,048 26.7 % -9.66%

Managers

Managers TitleAgeSince
Yong Qun Tang CEO
 Chief Executive Officer 49 03-12-31
Xiao Jie Qian DFI
 Director of Finance/CFO 44 10-12-31
Xi Wei Huang BRD
 Director/Board Member 54 11-03-31

Members of the board

Members of the board TitleAgeSince
Xi Wei Huang BRD
 Director/Board Member 54 11-03-31
Ping Shi BRD
 Director/Board Member 62 19-05-15
Yong Qun Tang CEO
 Chief Executive Officer 49 03-12-31
Ju Hua Xie BRD
 Director/Board Member 73 08-03-30
Zu Qing Liu CHM
 Chairman 74 11-03-02
Suo Qing Tian BRD
 Director/Board Member 61 15-06-10
Yi Jin BRD
 Director/Board Member 70 15-06-10
Xiao Ming Ma BRD
 Director/Board Member 49 19-05-15
Guo Qing Cui BRD
 Director/Board Member 68 20-05-24

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,620,403,199 432,667,997 ( 26.70 %) 3,754,515 ( 0.2317 %) 26.70 %

Shareholders

NameEquities%Valuation
Ju Hua Xie
27.23 %
439,682,951 27.23 % 682 M ¥
Jiangsu State-Owned Assets Sup. & Admin. Commission
21.15 %
341,540,589 21.15 % 530 M ¥
Yong Qun Tang
19.81 %
319,905,529 19.81 % 496 M ¥
Aegon-Industrial Fund Management Co., Ltd.
4.863 %
78,517,327 4.863 % 122 M ¥
Xi Wei Huang
4.376 %
70,654,217 4.376 % 110 M ¥
Bank of Communications Schroder Fund Management Co., Ltd.
1.069 %
17,252,864 1.069 % 27 M ¥
Everbright PGIM Fund Management Co. Ltd.
0.5875 %
9,485,267 0.5875 % 15 M ¥
China Southern Asset Management Co., Ltd.
0.5812 %
9,383,906 0.5812 % 15 M ¥
Qian Hai Life Insurance Co., Ltd.
0.4542 %
7,333,412 0.4542 % 11 M ¥
Ying Ding
0.3867 %
6,244,377 0.3867 % 10 M ¥
NameEquities%Valuation
Gui Ping Wu
2.342 %
47,320 2.342 % 73 395 ¥

Company contact information

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.

16 Xuefu Road Nanjing High-Tech Industrial Zone

210061, Nanjing

+86 25 8699 0701

http://www.nkf-pharma.com
address Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.(603707)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.7 CNY
Average target price
16.32 CNY
Spread / Average Target
+19.09%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD. Stock Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
-8.67% 3.05B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 704B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.59% 577B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.36% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.81% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-3.69% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 603707 Stock
  4. Company Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.